In a bumper week for new biotech financings, debutante Kardigan ruled the roost with a $300 million first round that will ...

N-Power Medicine, backed by Merck GHI, announced the acquisition of Syapse Holdings. Samsung Biologics and LigaChem extended their ADC services deal. Publicis Worldwide merged with Leo Burnett to form ...

It’s a kind of control that no one has ever tried before in patients,” Tune’s chief scientific officer said Monday.

Tune Therapeutics, an epigenome-editing company with origins at Duke University, has raised over $175 million in financing to advance a potential treatment for chronic hepatitis B and other diseases.

Its lead candidate Tune-401, which aims to repress viral DNA that contributes to infection, has entered into clinical trials in New Zealand and Hong Kong.

Investors clearly appreciate the song Tune Therapeutics is singing, handing over $175 million in series B funds as the ...

The biotech plans to use the funding to advance clinical testing of an epigenetic silencing therapy it hopes could treat ...

A Durham biotech firm founded on technology built at Duke University has raised $175 million to fund clinical trials of its ...

Tune Therapeutics, a biotech company with headquarters in Seattle and Durham, N.C., raised $175 million in one of the largest ...

Leading epigenome editing company Tune Therapeutics (Tune) today announced the completion of over $175M in financing led by New Enterprise Associates, Yosemite, Regeneron Ventures and Hevolution ...